Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene transfer in haematological malignancy

M K Brenner1

  • 1St Jude Children's Research Hospital, Cell and Gene Therapy Program, Memphis, TN 38105-2794, USA.

Annals of Medicine
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

A whole blood model of thrombocytopenia that controls platelet count and hematocrit.

Annals of hematology·2016
Same author

Delayed Induction of Proto-Oncogene Expression in B-CLL Cells by Tumor Necrosis Factor.

Leukemia & lymphoma·2016
Same author

Neuropathic dermatomes and cutaneous ulceration in patients with chronic GVHD.

Bone marrow transplantation·2014
Same author

Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma.

Bone marrow transplantation·2013
Same author

The immunogenicity of virus-derived 2A sequences in immunocompetent individuals.

Gene therapy·2013
Same journal

Integrative profiling of oral fungal communities across <i>Mycobacterium Tuberculosis</i> burden groups in Xpert-positive patients.

Annals of medicine·2026
Same journal

Prevalence and determinants of alcohol use disorder and its association with adherence to antihypertensive therapy among adult hypertensive patients in a hospital setting, Northwest Ethiopia.

Annals of medicine·2026
Same journal

Early detection of severe fetal growth restriction using multimodal deep learning based on ultrasound and prenatal biomarkers.

Annals of medicine·2026
Same journal

Tinnitus, hyperacusis and somatic complaints in a diverse Norwegian clinical population: implications for assessment and rehabilitation.

Annals of medicine·2026
Same journal

Epidemiological analysis of acute poisoning cases based on Poison control center data from 2021 to 2024.

Annals of medicine·2026
Same journal

Pediatric nurses' stress and their knowledge, attitudes, and practices towards first-aid for pediatric trauma: a latent profile analysis.

Annals of medicine·2026
See all related articles

Gene transfer, initially for inherited disorders, now treats malignant diseases. Current vector limits exist, but gene transfer complements existing therapies for blood cancers.

Area of Science:

  • Oncology
  • Genetics
  • Biotechnology

Background:

  • Gene transfer was initially proposed for inherited monogenic disorders.
  • Current clinical gene transfer protocols primarily target malignant diseases.
  • Existing vector technologies present limitations for broader therapeutic use.

Purpose of the Study:

  • To review the current applications of gene transfer in treating hematological malignancies.
  • To discuss forthcoming applications of gene transfer in this field.

Main Methods:

  • Review of current clinical protocols and research in gene transfer for hematological malignancies.
  • Analysis of existing and emerging vector technologies.

Main Results:

Related Experiment Videos

  • Gene transfer is successfully used to complement established therapies for hematological malignancies.
  • Despite vector limitations, gene transfer shows significant therapeutic potential.

    • Conclusions:

    • Gene transfer is a valuable tool in managing hematological malignancies.
    • Advancements in vector technology are expected to expand therapeutic applications.